Shkreli's KaloBios buys Chagas disease drug rights, shares soar
0
(Reuters) - KaloBios Pharmaceuticals Inc, which recently appointed controversial head of Turing Pharmaceuticals Martin Shkreli as CEO, said it was acquiring worldwide rights to a compound being developed for the treatment of Chagas disease.